ZIVO Bioscience, Inc.
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $157.2K | $27.7K | $0 | $0 | $20.0K | $0 | $0 | $0 |
| Cost of Revenue | $108.3K | $16.0K | $0 | — | — | — | — | — |
| Gross Profit | $49.0K | $11.6K | $0 | — | — | — | — | — |
| Gross Margin | 31.1% | 42.0% | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $3.1M | $1.4M | $2.2M | $2.0M | $3.8M | $2.3M | $2.8M | $2.4M |
| SG&A Expense | $10.3M | $5.9M | $6.5M | $6.7M | $4.8M | $4.1M | $1.4M | $2.1M |
| Operating Income | $-13.4M | $-7.3M | $-8.7M | $-8.6M | $-8.6M | $-8.4M | $-6.1M | $-6.3M |
| Operating Margin | -8,498.9% | -26,267.7% | — | — | -42,778.4% | — | — | — |
| Interest Expense | — | $23.8K | $13.3K | $44.7K | $97.6K | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-13.4M | $-7.8M | $-8.7M | $-8.8M | $-9.1M | $-11.5M | $-14.6M | $-10.0M |
| Net Margin | -8,513.4% | -28,127.2% | — | — | -45,528.6% | — | — | — |
| EPS (Basic) | — | — | — | — | $-0.02 | $-0.04 | $-0.09 | $-0.07 |
| EPS (Diluted) | $-4.23 | $-4.60 | — | — | $-0.02 | $-0.04 | $-0.09 | $-0.07 |
| Shares Outstanding (Basic) | — | — | 1.6M | 9.4M | 5.2M | 413.0M | 180.0M | 141.1M |
| Shares Outstanding (Diluted) | 3.2M | 1.7M | 1.6M | 9.4M | 5.2M | 413.0M | 180.0M | 141.1M |
| Dividends Per Share | — | $3.11 | — | — | — | — | — | — |